These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 24970875)

  • 1. The approval process for biosimilar erythropoiesis-stimulating agents.
    Wish JB
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1645-51. PubMed ID: 24970875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The emerging role of biosimilar epoetins in nephrology in the United States.
    Fishbane S; Shah HH
    Am J Kidney Dis; 2015 Apr; 65(4):537-42. PubMed ID: 25582283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars-Emerging Role in Nephrology.
    Wish JB
    Clin J Am Soc Nephrol; 2019 Sep; 14(9):1391-1398. PubMed ID: 30082337
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States.
    Anand S; Al-Mondhiry J; Fischer K; Glaspy J
    Expert Rev Clin Pharmacol; 2021 Jan; 14(1):1-8. PubMed ID: 33307871
    [No Abstract]   [Full Text] [Related]  

  • 5. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar Erythropoiesis-Stimulating Agents in Chronic Kidney Disease.
    Shah HH; Fishbane S
    Adv Chronic Kidney Dis; 2019 Jul; 26(4):267-271. PubMed ID: 31477257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State-of-the-art biosimilar erythropoietins in the management of renal anemia: lessons learned from Europe and implications for US nephrologists.
    Covic A; Abraham I
    Int Urol Nephrol; 2015 Sep; 47(9):1529-39. PubMed ID: 26223197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Systematic Review of U.S. Biosimilar Approvals: What Evidence Does the FDA Require and How Are Manufacturers Responding?
    Hung A; Vu Q; Mostovoy L
    J Manag Care Spec Pharm; 2017 Dec; 23(12):1234-1244. PubMed ID: 29172975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The First 2 Years of Biosimilar Epoetin for Cancer and Chemotherapy-Induced Anemia in the U.S.: A Review from the Southern Network on Adverse Reactions.
    Bennett CL; Nagai S; Bennett AC; Hoque S; Nabhan C; Schoen MW; Hrushesky WJ; Luminari S; Ray P; Yarnold PR; Witherspoon B; Riente J; Bobolts L; Brusk J; Tombleson R; Knopf K; Fishman M; Yang YT; Carson KR; Djulbegovic B; Restaino J; Armitage JO; Sartor OA
    Oncologist; 2021 Aug; 26(8):e1418-e1426. PubMed ID: 33586299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic Products.
    Moore TJ; Mouslim MC; Blunt JL; Alexander GC; Shermock KM
    JAMA Intern Med; 2021 Jan; 181(1):52-60. PubMed ID: 33031559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.
    Kalantar-Zadeh K
    Am J Nephrol; 2017; 45(3):235-247. PubMed ID: 28142147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the biosimilar approval and extrapolation process-A case study of an epoetin biosimilar.
    Agarwal AB; McBride A
    Crit Rev Oncol Hematol; 2016 Aug; 104():98-107. PubMed ID: 27317353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The complexities of biosimilars and the regulatory approval process.
    Lucio S
    Am J Manag Care; 2018 Jun; 24(11 Suppl):S231-S236. PubMed ID: 29957908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
    Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
    Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease.
    Hörl WH
    Drugs; 2013 Feb; 73(2):117-30. PubMed ID: 23338536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biosimilars in Oncology in the United States: A Review.
    Nabhan C; Parsad S; Mato AR; Feinberg BA
    JAMA Oncol; 2018 Feb; 4(2):241-247. PubMed ID: 28727871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The US approach to biosimilars: the long-awaited FDA approval pathway.
    Calvo B; Zuñiga L
    BioDrugs; 2012 Dec; 26(6):357-61. PubMed ID: 23030677
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.